Octreotide for unresectable hepatocellular carcinoma: Beyond the first sight [3]

Journal of Clinical Gastroenterology

Volumn 40, Issue 1, 2006, Pages 86-87

  Samonakis, Dimitrios N ^a   Christodoulakis, Nikolaos ^a   Kouroumalis, Elias A ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANTINEOPLASTIC ACTIVITY; AUTORADIOGRAPHY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; IMMUNOHISTOCHEMISTRY; KUPFFER CELL; LETTER; LIVER CELL CARCINOMA; LIVER SCINTISCANNING; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; TREATMENT OUTCOME; BIOPSY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; LIVER TUMOR; MORTALITY; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; OCTREOTIDE; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33644972460     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000190778.50279.26     Document Type: Letter

References (16)

1. Slijkhuis WA, Stadheim L, Hassoun ZM, et al. Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol. 2005;39:333-338.
2. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5-S16.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
4. Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998;42:442-447.
5. Samonakis DN, Moschandreas J, Arnaoutis T, et al. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep. 2002;9:903-907.
6. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of Sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology. 2002;49:1245-1250.
7. Raderer M, Hejna MH, Kurtaran A, et al. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analogue lanreotide. Am J Gastroenterol. 1999;94:278-279.
8. Siveke JT, Herberhold C, Folwaczny C. Complete regression of advanced HCC with long acting octreotide. Gut. 2003;52:1531.
9. Raderer M, Hejna MH, Muller C, et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol. 2000;16:1197-1201.
10. Yuen MF, Poon RT, Lai CL, et al. A randomised placebo-controlled study of long acting octreotide for the treatment of advance hepatocellular carcinoma. Hepatology. 2002;36:687-691.
11. Kouroumalis E, Samonakis D, Skordilis P. Octreotide treatment of hepatocellular carcinoma. Hepatology. 2003;37:447.
12. Allgeier HP, Becker G, Olschewski M, et al. Octreotide treatment in patients with advance hepatocellular carcinoma: first results of the randomized placebo-controlled double-blind Hector trial. Hepatology. 2003;38(suppl 1):1243.
13. Reubi JC, Zimmermann A, Jonas S, et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut. 1999;45:766-774.
14. Blaker M, Schmitz M, Gocht A, et al. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol. 2004;41:112-118.
15. Reynaert H, Rombouts K, Vandermonde A, et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004;53:1180-1189.
16. Notas G, Kolios G, Mastrodimou N, et al. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. J Hepatol. 2004;40:792-798.